The ability to block overactive MYC transcription is of interest because of the genes’ involvement in not only overall pathogenesis, but also its association with relapse and refractory DLBCL (Mondello et al., 2017). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.